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Abstract
Background: The prevalence of both chronic coronary syndrome (CCS) and its risk factors is alarming in Saudi Arabia
and only a minority of patients achieve optimal medical management. Context-speciﬁc CCS guidelines outlining best
clinical practices are therefore needed to address local gaps and challenges.
Consensus panel: A panel of experts representing the Saudi Heart Association (SHA) reviewed existing evidence and
formulated guidance relevant to local clinical practice considering the characteristics of the Saudi population, the Saudi
healthcare system, its resources and medical expertise. They were reviewed by external experts to ensure scientiﬁc and
medical accuracy.
Consensus ﬁndings: Recommendations are provided on the clinical assessment and management of CCS, along with
supporting evidence. Risk reduction through non-pharmacological therapy (lifestyle modiﬁcations) remains at the core
of CCS management. Great emphasis should be placed on the use of available pharmacological options (anti-anginal
therapy and event prevention) only as appropriate and necessary. Lifestyle counseling and pharmacological strategy
must be optimized before considering revascularization, unless otherwise indicated. Revascularization strategies should
be carefully considered by the Heart Team to ensure the appropriate choice is made in accordance to current guidelines
and patient preference.
Conclusion: Conscientious, multidisciplinary, and personalized clinical management is necessary to navigate the
complex landscape of CCS in Saudi Arabia considering its population and resource differences. The reconciliation of
international evidence and local characteristics is critical for the improvement of healthcare outcomes among CCS patients in Saudi Arabia.
Keywords: Chronic coronary syndrome, Saudi Arabia, Guidelines
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1. Introduction

C

oronary artery disease (CAD) is a dynamic
and progressive pathological process characterized by atherosclerotic plaque accumulation in
the epicardial arteries, potentially associated with
vasospastic disease or thrombus in situ. The
epicardial disease can be obstructive or nonobstructive and the vasospastic disease can be focal
or diffuse. CAD can be both stable and unstable in
its clinical presentation; its management is different
between acute coronary syndromes (ACS) and the
chronic pattern of the disease, chronic coronary
syndromes (CCS) (formerly referred to as stable
CAD) [1].
The overall prevalence of CAD of 5.5% was reported in Saudi Arabia between 1995 and 2000 [2].
Almost half of all cardiovascular disease-related
deaths in the world in 2019 was attributed to CAD
[3]. Some of the highest rates of age-standardized
cardiovascular disease (CVD)-related disabilityadjusted life-years are found in the North Africa and
Middle East region [3]. In Saudi Arabia, the agestandardized CVD-related deaths has increased
from 20 to 30% between 2010 and 2019 [4,5]. Moreover, cardiovascular diseases is the primary cause of
death as well as years lived with disability and agestandardized disability-adjusted life-years [4,5].
CAD is very common in the Middle East, with 55%
of heart failure (HF) in Middle Eastern Arab countries attributed to CAD [4]. A recent study from
Saudi Arabia (HEARTS-chronic) showed that CAD
can be identiﬁed as the underlying cause of 38% of
HF cases [6].
The CLARIFY (ProspeCtive observational LongitudinAl RegIstry oF patients with stable coronary
arterY disease) study investigated the long-term
outcomes of CCS in 45 countries, including the
Middle East (and Saudi Arabia). Patients from the
Middle East had the highest body mass index (BMI),
highest prevalence of diabetes, as well as the highest
overall use of secondary prevention therapy [7].
Patients in this region are also distinctly younger, as
age of onset of cardiovascular events (acute
myocardial infarction) is at least 10 years lower in
the Middle East compared to other regions [8e10]. A
study modeling the burden of cardiovascular disease in the Saudi population projected that the
prevalence of CVD will increase to 479,500 Nationals
by 2035, incurring close to $10 billion in direct and
indirect costs [11].
Considering the incidence of CCS and its risk
factors in Saudi Arabia, the Saudi Heart Association
(SHA) developed an ofﬁcial position statement on
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Abbreviation list
ACC
ACE
ACS
AHA
ARB
BMI
BP
CABG
CAC
CAD
CBC
CCB
CCS
CCTA
CMR
COVID19
CT
CVD
DAPT
DOAC
ECG
ECHO
ESC
FFR
HbA1c
HF
ICA
INOCA
LAD
LDL-C
LV
LVEF
MACE
MI
MPI
NICE
PCI
PET
RASi
SARSCoV-2
SDS
SHA
SPECT

American college of cardiology
Angiotensin-converting enzyme
Acute Coronary syndromes
American heart association
Angiotensin receptor blockers
Body mass index
Blood pressure
Coronary artery bypass grafting
Coronary artery calciﬁcation
Coronary artery disease
Complete blood count
Calcium channel blockers
Chronic coronary syndrome
Coronary computed tomography angiography
Cardiac magnetic resonance
Coronavirus disease 2019
Computed tomography
Cardiovascular disease
Dual antiplatelet therapy
Direct oral anticoagulant
Electrocardiogram
Echocardiography
European society of cardiology
Fractional ﬂow reserve
Hemoglobin A1c
Heart failure
Invasive coronary angiography
Ischemia and No Obstructive CAD
Left Anterior Descending
Low-density lipoprotein cholesterol
Left ventricle
Left ventricular ejection fraction
Major adverse cardiovascular events
Myocardial infarction
Myocardial perfusion imaging
National Institute for Health and Clinical
Excellence
Percutaneous coronary intervention
Positron emission tomography
Renin angiotensin system inhibitor
Severe acute respiratory syndrome coronavirus 2
Summed Difference Score
Saudi heart association
Single-photon emission CT

the management of these conditions in respect of
available resources and expertise. Local CCS
guidelines are needed to outline best clinical practices and improve access to healthcare services for
all Saudi patients.

2. Methods
A series of meetings were held by a panel of experts to review existing evidence, international
guidelines and formulate guidance relevant to local
clinical practice considering the individual
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characteristics of the Saudi population, the Saudi
healthcare system, its available resources and
medical expertise. Data were reviewed by specialized subcommittees, who then proposed relevant
recommendations. The overall guidelines were then
reviewed by the steering committee as well as a
secondary external expert panel to ensure accuracy,
scientiﬁc integrity and relevance to the context of
Saudi Arabia.
The guidelines followed the format of the Saudi
Heart Association Guidelines and recommendations (Table 1).

3. Results - consensus statements
3.1. Clinical assessment
3.1.1. Risk assessment
Predictive models have been proposed to assess
the pre-test probability of obstructive CAD and
have been used in clinical practice since the introduction of the ﬁrst model by Diamond and Forrester
in 1979 [12]. These models attempt to predict the
clinical likelihood of CAD based on age, sex and the
nature of symptoms and undergo constant scrutiny
and updates to improve their performance. In fact,
CAD overestimation remains a notable issue in
clinical pre-test probability assessment, even after
the update of older models. Both the original Diamond-Forrester model and its 2011 update were
found to overestimate the prevalence of obstructive
CAD [13]. The predictive model proposed in the
2013 European Society of Cardiology (ESC) guidelines on the management of stable CAD [14] was
also found to lead to the overestimation of the
prevalence of obstructive disease by almost twothirds [15e19]. This led to its update considering the
contribution of pre-test probability overestimation
to low diagnostic yield in invasive and non-invasive
testing [19]. The newer ESC model proposed in 2019
integrated patients whose main symptom upon
presentation is dyspnea and has since been

validated and found to provide a more reasonable
classiﬁcation of the likelihood of obstructive CAD in
patients compared to the previous 2013 model, as
well as other models (National Institute for Health
and Clinical Excellence (NICE) 2016 model and the
CAD Consortium basic score) [20e23]. Using pretest probability assessment, diagnostic imaging can
be safely avoided or delayed in patients with pretest probability<15% in the absence of compelling
reasons [15,16], which will in turn reduce unnecessary use of resources and unnecessary testing in
patients with stable chest pain/suspected CAD.
Despite this, a minority of centers around the world
follow guideline recommendations to include pretest probability in the clinical assessment of patients
with suspected CAD [24].
In addition to sex, age and the nature of symptoms, it might be useful to also consider CVD risk
factors (i.e. possible heredity of CVD, dyslipidemia,
diabetes, hypertension, and lifestyle factors such as
smoking) when looking to identify patients with
obstructive CAD [1,14,25e27]. However, the use of
CVD risk factors to improve pre-test probability
assessment still requires optimization. Coronary
calcium score was another factor shown to improve
clinical pre-test probability calculation through
several models [28,29], further highlighting the need
for continuous improvement of available prediction
scores to reduce CAD overestimation.
The ESC models were developed mainly using
patients from low CVD risk regions [1]. This could
further limit their predictive ability in high-risk regions such as Saudi Arabia, where modiﬁable cardiovascular risk factors (e.g. dyslipidemia,
hypertension, obesity, diabetes, smoking) are highly
prevalent and are most often synchronous (more
than three cardiovascular risk factors in almost half
of the population) and the onset of cardiovascular
disease is one to two decades younger in age [30].
Based on risk factors, it is estimated that a signiﬁcant portion of the Saudi population will develop
severe coronary events (myocardial infarction or

Table 1. Saudi Heart Association classes of recommendations.

coronary death) [31] or CVD [32] in the next 10
years. A gender-based approach might be appropriate in Saudi Arabia, where women seem to more
often present with high risk CVD risk factors [33]
and suffer from more adverse outcomes after surgery for CAD [34]. Adequate clinical assessment
including medical history, patient characteristics
and diagnostic imaging (when needed) coupled
with comprehensive therapy and rehabilitation
should improve the timely detection and management of CAD without overburdening healthcare
systems with unnecessary medical services.
3.1.2. History and physical examination
All patients with documented CAD should be
managed as CCS to reduce ACS, MI, stroke and
death, although many patients presenting with
symptoms suggesting CCS do not have documented
CAD. Symptom type and duration in relation to
clinical presentation should be obtained as part of
establishing patient history in addition to associated
traits. A focused cardiovascular assessment is
advisable to rule out a possible ACS or other causes
of chest pain that could be severe or life-threatening
and to identify complications. History and physical
examination ﬁndings should be considered collectively as to properly guide further diagnostic testing
and management plan. Chest pain should be
assessed in the context of age and gender as
accompanying symptoms are more frequent among
females [35,36] and acute coronary syndrome is
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likely to occur among older patients [37e39];
Furthermore, it is also important to consider alternative diagnoses (Fig. 1). It is crucial to differentiate
stable versus unstable angina (i.e. rest chest pain for
long duration, new-onset chest pain or equivalent,
crescendo angina). Further testing is necessary to
diagnose CCS [40] and its need remains dependent
on pre-test probability, as outlined in sections 3.1.3
and 3.1.4. For more information on the deﬁnition
and characteristics, duration and intensity of
symptoms, please refer to the CAD modules available in the SHA Virtual Academy (https://shaacademy.com/).
3.1.3. Initial diagnostic evaluation
Basic diagnostic evaluation in patients with suspected CCS includes laboratory testing, a resting
electrocardiogram (ECG), resting echocardiography,
and a chest X-ray in speciﬁc patient groups.
3.1.3.1. Biochemical testing. Laboratory tests are
requested to detect potential causes of ischemia, as
well as to diagnose cardiovascular risk factors and
other associated conditions. In addition to a complete blood count (CBC) including hemoglobin,
renal function, fasting plasma glucose and glycated
hemoglobin (HbA1c) should be determined to rule
out anemia, chronic kidney disease and diabetes,
respectively. Moreover, a lipid proﬁle (including
total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol (LDL-C),

Fig. 1. Top 9 causes of chest pain in the emergency department based on age (weighted percentage; excluding nonspeciﬁc chest pain). Created using
data from Hsia, RY, et al. [37].
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Table 2. Recommendations for initial basic diagnostic testing for patients with suspected CCS.

No
1

Recommendaon
Complete blood count (CBC), creanine, esmaon of glomerular ﬁltraon rate and lipid
proﬁle are recommended in all paents with suspected CAD.

2

Screening for diabetes is recommended in all paents with suspected or established CAD
(including HBA1c, fasng plasma glucose). In the event that ﬁndings are inconclusive
(HBA1c, fasng plasma glucose), glucose tolerance test is recommended.

3

Thyroid funcon test is recommended in case of suspicion of thyroid dysfuncon

CAD = coronary artery disease; CBC = Complete Blood Count; HbA1c = glycated hemoglobin.

Table 3. Recommendations for electrocardiogram use in the initial evaluation of patients with suspected
coronary artery disease.

No Recommendaon
1

A resng 12 leads ECG is recommended in all paents with chest pain or equivalent.

ECG = electrocardiogram.

Table 4. Recommendations for echocardiogram for patients with suspected coronary artery disease.

No
1

Recommendaon
A resng transthoracic echocardiogram is recommended for all paents to:
(1) eliminate other causes of chest pain
(2) Detect regional wall moon abnormalies suggesve of CAD
(3) Assess LVEF for risk straﬁcaon
(4) Assess diastolic funcon

CAD = coronary artery disease; LVEF = le ventricular ejecon fracon.

Table 5. Recommendation for chest X-ray for patients with suspected coronary artery disease.

No Recommendaon
1

Chest X-ray may be considered to assess signs of HF, rule out pulmonary diseases, other
non-cardiac causes for chest pain.

HF: heart failure

187

Table 6. Diagnostic accuracy of noninvasive modalities for detection of CAD.
Modality

Sensivity

Speciﬁcity

CT Angiography

91

93

Stress Echocardiography

79

87

MPI-SPECT

86

74

MPI-PET

89

90

Stress MR perfusion

91

81

Stress MR wall moon

83

86

MR coronary angiography

73

86

Exercise electrocardiogram

68

77

CT: computed tomography; MPI: myocardial perfusion imaging; MR: magnec resonance; PET: positron
emission tomography; SPECT: single photon emission computed tomography
Reprinted with permission of Anderson Publishing Ltd. from Al-Shehri, H., Small, G., & Chow, B. J. (2011).
Cardiac CT, MR, SPECT, ECHO, and PET: What test, when?. Applied Radiology, 40(5), 13. ©Anderson
Publishing Ltd.

Fig. 2. Factors of the clinical likelihood of obstructive coronary artery disease. CAD: coronary artery disease; CT: computed tomography; CVD:
cardiovascular disease; ECG: electrocardiogram; LV: left ventricle.
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Table 7. Pretest probability of coronary artery disease by age, gender and symptoms.
Age
(Years)

Sex

Typical/Deﬁnite
Angina

Atypical/Probable
Chest Pain

Non-anginal
Chest Pain

Asymptomac

30-39

Men

Intermediate

Intermediate

Low

Very low

Women

Intermediate

Very low

Very low

Very low

Men

High

Intermediate

Intermediate

Low

Women

Intermediate

Low

Very low

Very low

Men

High

Intermediate

Intermediate

Low

Women

Intermediate

Intermediate

Very low

Very low

Men

High

Intermediate

Intermediate

Low

Women

High

Intermediate

Intermediate

Low

40-49

50-59

60-69

Reprinted with permission of Anderson Publishing Ltd. from Al-Shehri, H., Small, G., & Chow, B. J. (2011).
Cardiac CT, MR, SPECT, ECHO, and PET: What test, when?. Applied Radiology, 40(5), 13. ©Anderson
Publishing Ltd.

Table 8. High-risk features of noninvasive modalities.
Modality

High risk features

Exercise Treadmill Tesng

Duke score < -11
(ST-segment depression, exercise me and
symptoms)
Time to onset of ST-segment depression
ST-segment elevaon
Time to resoluon of ST-segment depression
Exercise induced ventricular arrhythmias

Cardiac CT

Le main stenosis ≥ 50%
3 vessel disease
2 vessel disease including proximal LAD

MPI

Large reversible perfusion defect
Mulple perfusion defects
SDS ≥13
Post-stress transient ischemic dilaon
Post-stress right ventricle uptake
Post-stress lung uptake
Abnormal post-stress LVEF

Stress ECHO

Post-stress new regional wall abnormalies
Post-stress global LV impairment
Diastolic dysfuncon
Post-stress LV cavity dilataon
Mitral regurgitaon

CMR

SDS ≥7
Presence of late gadolinium enhancement
Reversible perfusion defects

CMR: cardiac magnec resonance; CT: computed tomography; ECHO: echocardiography; LAD: Le
Anterior Descending; LV: le ventricle; LVEF: le ventricular ejecon fracon; MPI: myocardial perfusion
imaging; SDS: Summed Diﬀerence Score
Reprinted with permission of Anderson Publishing Ltd. from Al-Shehri, H., Small, G., & Chow, B. J. (2011).
Cardiac CT, MR, SPECT, ECHO, and PET: What test, when?. Applied Radiology, 40(5), 13. ©Anderson
Publishing Ltd.

lipoprotein a (Lp(a)) and triglycerides) would reﬂect
risk proﬁles and the need for treatment (Table 2).
In case of clinical suspicion of acute coronary
syndrome, refer to relevant guidelines.
3.1.3.2. 12-lead electrocardiogram. Resting 12 lead
ECG allows the detection of ST-segment and T wave
changes as well as indirect signs of CAD such as
signs of prior myocardial infarction (MI) (pathological Q waves), conduction abnormalities or arrhythmias and is recommended for all patients with
chest pain or equivalent symptoms (Table 3).
3.1.3.3. Echocardiogram. Transthoracic echocardiography commonly provides key insights into cardiac
function and anatomy. Reduction in left ventricle
(LV) systolic function, diastolic dysfunction, regional
wall motion abnormalities may indicate ischemic
myocardial damage [1]. Echocardiography plays an
important role in the diagnosis of coexisting diseases of the heart, such as valvular heart diseases
[41] (Table 4).
3.1.3.4. Chest X-ray. Chest X-ray could be helpful in
evaluating patients with suspected HF or pulmonary problems, and to exclude other possible reasons of chest pain (Table 5).
3.1.4. Non-invasive diagnostic testing
3.1.4.1. General considerations. A wide diagnostic
armamentarium is available for disease diagnosis,
including treadmill stress tests, stress echocardiography (ECHO), myocardial perfusion imaging (MPI)
through both single photon emission computed tomography (SPECT) and positron emission
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tomography (PET), coronary computed tomography
angiography (CCTA), and cardiac magnetic resonance imaging (CMR).
However, making the optimal choice of diagnostic
test can be challenging. Table 6 shows the diagnostic
accuracy of different noninvasive approaches for the
detection of CAD. Understanding the patient pretest probability of CAD and the risk, advantages and
shortcomings of each modality will prove useful for
test selection (Fig. 2). In addition to this, site
expertise, availability, and cost will affect the choice
of test [42].
Noninvasive tests assess two essential features
that are mandatory for the patient care:
What are the patient's diagnosis and prognosis?
Pre-test probability assessment is crucial when
considering the need for testing, test selection/
appropriateness, and test result interpretation. The
clinician can estimate the patient's pre-test probability for CAD based upon age, gender and quality
of symptoms [43] (Table 7). The detection of patients
with obstructive CAD was also shown to be
improved by clinical models taking into consideration risk factors for CCS [1,14,25e27], resting ECG
changes, or coronary calciﬁcation calcium obtained
by computed tomography (CT) [28,29] (Fig. 2).
3.1.4.2. Functional versus anatomical imaging for
CAD. Cardiac imaging modalities fall into two,
sometimes overlapping, comprehensive groups.
Insights obtained from modalities such as CCTA
and CMR angiography primarily reﬂect anatomical
information for the evaluation of coronary stenosis.
On the other hand, functional imaging modalities
such as stress ECHO, SPECT, PET, and CMR, help
in the diagnosis of ischemia. The choice between

Table 9. Recommendations on exercise electrocardiogram in the initial diagnostic management of patients with suspected coronary artery disease.

No

Recommendaon

1

Exercise ECG is recommended for the assessment of exercise tolerance, symptoms,
arrhythmias, BP response, and event risk in selected paents (When diagnosc or
therapeuc strategy will be aﬀected)

2

Exercise ECG may be considered as an alternave test to rule-in and rule-out ischemia in
case non-invasive imaging is inaccessible

3

Exercise ECG may be considered in paents receiving therapy to assess symptom control
and ischemia.

4

Exercise ECG is not recommended for the intent of diagnosis in paents with >_0.1 mV STsegment depression on resng ECG or in paents receiving treatment with digitalis.

BP: blood pressure; ECG: electrocardiogram
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diagnostic methods, be it predominately anatomical
or functional, should be based on the clinical
question.
Available evidence shows a very low annual rate
of cardiac events in patients who were found to be at
low-risk of CAD through noninvasive tests (<1%)
[44]. Based on this, medical treatment can be safely
administered and further investigation is not
necessary except in the case of uncontrolled or
emerging/changed symptoms. The Clinical Outcomes Utilizing Revascularization and Aggressive
Drug Evaluation (COURAGE) trial [45] and the
Initial Invasive or Conservative Strategy for Stable
Coronary Disease (ISCHEMIA) trial [46], the largest
randomized trials of patients with CCS, support this
approach seeing as the use of revascularization in
addition to optimal medical therapy was not found
to lead to improved outcomes compared with initial
optimal medical therapy alone.
3.1.4.3. Cardiac testing based on pretest probability of
CAD
3.1.4.3.1. Low pretest probability of CAD. The need
for noninvasive imaging in case of low pre-test
probability of CAD remains indeterminate. The
American Heart Association/American College of
Cardiology (AHA/ACC) guidelines for exercise
testing provides low level (IIb) recommendation in
this patient group [43]. When pre-test probability of
CAD is low, exercise treadmill testing could be
beneﬁcial by facilitating patient access to other
diagnostic modalities. However, it should be noted
that this approach have a relatively modest sensitivity and speciﬁcity for CAD detection (68% and
77%, respectively) with false-negative and falsepositive test results [47]. It is important to note that
exercise treadmill testing alone is not diagnostic and
does not rule out underlying CAD. Further testing
(coronary calcium score, CT) is warranted to
completely exclude the diagnosis of CAD.
Conversely, exercise treadmill testing still has
prognostic value when used in the right patient
population (low pre-test probability as opposed to
intermediate or high pre-test probability). The Duke
treadmill score can be used for the detection of
patients who are at high risk of a future cardiac
event [48]. Table 8 shows other indicators of poor
prognosis in severe CAD by exercise treadmill
testing [49e51] (see Table 9).
3.1.4.3.2. Intermediate pretest probability of CAD.
Patients with intermediate pre-test probability of
CAD are expected to beneﬁt the most from diagnostic and prognostic testing. In this population,

conﬁrming or disprove the presence of CAD is
essential.
3.1.4.3.3. High pretest probability of CAD. In the
case of high pre-test probability of CAD or alreadydocumented CAD, SPECT, PET, stress ECHO or
CMR may be used for risk stratiﬁcation and prognosis. This would yield appropriate information for
therapy guidance and establishing the necessity of
invasive angiography and revascularization.
3.1.4.4. Anatomic testing
3.1.4.4.1. Coronary computed tomography angiography (CCTA). Coronary artery calciﬁcation (CAC)
detected by non-contrast enhanced CT is indicative
of atherosclerosis [52e54]. The superior prognostic
value of CAC compared to traditional risk factors
was evident in several studies [55e57]. One metaanalysis including 3924 symptomatic patients with a
3.5-year follow-up showed that patients with
CAC>0 had a yearly cardiac event rate of 2.6%, with
a notable lower rate (0.5%) observed among those
with 0 CAC [56].
The accuracy of CCTA in the detection of
atherosclerotic plaque is the main inﬂuence on its
clinical applications of CCTA. Several studies have
assessed the accuracy of CCTA for detection of
coronary artery stenosis compared to invasive coronary angiography (ICA) [58]; the sensitivity
reportedly varies between 86% and 100% and the
speciﬁcity between 91% and 98%. Given CCTA's
high negative predictive value, this modality may be
best used to exclude CAD and to limit ICA use for
the diagnosis of CAD [59,60]. This was conﬁrmed by
the DISCHARGE trial, which demonstrated comparable risk of major adverse cardiovascular events
in patients with stable chest pain and intermediate
pre-test probability of CAD when initially diagnosed with CT or ICA. It should be noted that evidence from other clinical trials (i.e. the PROMISE,
CONFIRM, and SCOT-Heart trials) show that
CCTA is associated with increased cost, overestimates the prevalence of disease and is associated
with a 50% increase in subsequent coronary angiography and revascularization with no differences
in mortality as compared with functional testing
[18,61e65]. Moreover, the use of CT for initial
diagnosis was associated with fewer complications
due to a major procedure [66]. Calculation of fractional ﬂow reserve with CT (FFR-CT) reﬂects estimated lesion-speciﬁc ischemia [67]. A meta-analysis
of available evidence supports the role of FFR-CT in
excluding the need for further testing in patients
with CCS and intermediate risk [68]. This approach

seems to be relatively safe, being associated with a
lower incidence of intermediate-term adverse
events [68]. It is therefore important to address gaps
in local practice and ensure the availability and
accessibility of FFR-CT in healthcare institutions.
In the current American College of Cardiology
Foundation appropriateness criteria guidelines for
cardiac CT and MR, CCTA is considered to be
suitable for the evaluation of intermediate risk patients with uninterpretable ECG or inability to exercise [69].
In addition to diagnostic accuracy, CCTA also
reﬂects the possibility of coronary events and death
(Table 8) [70].
3.1.4.4.1.1 Coronary CT angiography: limitations and
challenges The diagnostic accuracy of CCTA is
greatly dependent on image quality. It is therefore
necessary to ensure image quality is optimal
through adequate patient preparation and CCTA

protocol. Cardiac motion artifacts arise in patients
with elevated heart rates, and heart rate variability
[71,72].
The limitations of CCTA are several and include
exposure to ionizing radiation, the need for a slow
heart rate, arrhythmia, severe renal impairment,
extensive coronary artery calciﬁcations, and potential allergy to contrast. Recent technological
advancement in scanners have addressed some of
these limitations, reducing the need for a slow heart
rate and allowing imaging of patients with slow
atrial ﬁbrillation. Remarkable efforts have also made
use of available technologies and approaches to
limit CCTA's radiation dose [73,74].
3.1.4.4.2. MR angiography. Noninvasive visualization of the coronary artery with no exposure to
ionizing radiation is possible with coronary MR
angiography [75]. This modality is not without its
limitations, which include extended image duration,

Table 10. Recommendation for initial diagnostic imaging tests in the assessment of symptomatic patients with suspected CAD.

No

Recommendaon

1

non-invasive funconal imaging for myocardial ischemia or CCTA is recommended as the
inial test to diagnose CAD in symptomac paents with suspected CAD.

2

It is recommended that the choice of inial non-invasive diagnosc test be founded on
the PTP of CAD and other paent characteriscs with implicaons on test performance
(contraindicaons), local experse, cost and test accessibility.

3

funconal imaging for myocardial ischemia or invasive anatomical and funconal
invasive imaging is recommended for conﬁrmaon of the diagnosis of CAD in cases
where diagnosis could not be established based on CCTA, or CCTA reﬂected CAD of
uncertain funconal signiﬁcance.

4

Invasive coronary angiography is recommended as an inial diagnosc test for CAD in the
following cases:
high PTP,
severe symptoms uncontrolled by pharmacologic therapy or
typical angina at a low level of exercise,
high event risk* based on clinical evaluaon.

5

It is necessary that invasive funconal assessment be accessible and it should be used to
assess stenoses before revascularizaon when clinical signiﬁcance of lesion is in doubt.

6

CCTA should be considered as an alternave to invasive angiography if inconclusive or
non-diagnosc results were obtained from another non-invasive test

7

8
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CCTA is not recommended in case obtaining good image quality is doubul (e.g. extensive
coronary calciﬁcaon, irregular heart rate, signiﬁcant obesity, inability to cooperate with
breath-hold commands).
Coronary calcium detecon by CT is not an alternave to CCTA and is not recommended
to diagnose obstrucve CAD.

*: survived sudden cardiac death or potenally life-threatening ventricular arrhythmias and those
paents develop symptoms and signs of heart failure
CAD: coronary artery disease; CT: computed tomography; CCTA: coronary computed tomography
angiography; PTP: pre-test probability
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Fig. 3. Diagnostic algorithm for investigating suspected coronary artery disease. CAD: coronary artery disease; CCTA: coronary computed tomography angiography; ECG: electrocardiogram; ECHO: stress echocardiography; MPI: myocardial perfusion imaging.

lower spatial resolution, and reliance/variability
related to the operator. Moreover, MR angiography
has lower sensitivity and speciﬁcity compared to
CCTA, with an as of yet ambiguous clinical utility
[76,77].
3.1.4.5. Functional testing
3.1.4.5.1. MPI: SPECT and PET. MPI with SPECT is
a widely accessible test that makes use of stressors,
most commonly exercise. Other stressors may be
needed depending on each case; vasodilator stress is
indicated in patients with left bundle branch block
(LBBB), patients unable to exercise, and patients
unable to reach target heart rate [78]. Patients with
severe asthma or other conditions susceptible to
bronchospasm exacerbations are generally administrated dobutamine due to the contraindication of
some vasodilators, such as adenosine and dipyridamole. SPECT MPI was shown to have an overall
diagnostic sensitivity and speciﬁcity of 86% and
74%, respectively, by an extensive meta-analysis
[79]. MPI can be used to guide coronary intervention

seeing as SPECT perfusion abnormalities are closely
correlated with coronary artery perfusion territories
[80].
Available evidence suggests that PET might have
superior accuracy to SPECT MPI [81], with a mean
sensitivity and speciﬁcity of 89% (83%e100%) and
90% (73%e100%), respectively, in the diagnosis of
CAD [82e85]. The prognostic value of SPECT and
PET in patients with suspected or documented CAD
is supported by various studies as both modalities
allow the identiﬁcation of patients at high risk of
future cardiac events, as outlined in Table 8. These
patients can then be selected for invasive investigations and coronary intervention [86e88].
3.1.4.5.1.1 SPECT and PET: limitations and challenges
Radiation exposure and contraindications to the
type of stress test (exercise as a stressor or pharmacologic stressors) are main limitations of SPECT
and PET.
3.1.4.5.2. Stress echocardiography. Stress echocardiography is an established technique for the evaluation of CAD's functional signiﬁcance and for risk
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Fig. 4. Diagnostic algorithm for patients with known CAD and chest pain. * high risk features or previous revascularization. CAD: coronary artery
disease; CMR: cardiac magnetic resonance; ECG: electrocardiogram; ECHO: echocardiography; GDMT: guideline-directed medical therapy; PET:
positron emission tomography; SPECT: single-photon emission CT.

Table 11. Recommendations for patient with INOCA.

No

Recommendaon

1

Invasive coronary funcon tesng should be considered for beer diagnosis of INOCA and
risk straﬁcaon in paents with persistent stable chest pain and nonobstrucve CAD
with mild or worse myocardial ischemia (as observed on imaging)

2

Stress PET MPI with myocardial blood ﬂow reserve should be considered for the diagnosis
of microvascular dysfuncon and the improvement of risk straﬁcaon in paents with
persistent stable chest pain and nonobstrucve CAD.

3

Stress CMR with the addion of MBFR measurement should be considered for beer
diagnosis of coronary myocardial dysfuncon and MACE risk esmaon in paents with
persistent stable chest pain and nonobstrucve CAD.

4

Stress echocardiography with the addion of coronary ﬂow velocity reserve measurement
may be considered for beer diagnosis of coronary myocardial dysfuncon and for MACE
risk esmaon in paents with persistent stable chest pain and nonobstrucve CAD.

CAD: coronary artery disease; CMR: cardiac magnec resonance; MACE: major adverse cardiovascular
events; MPI: myocardial perfusion imaging; PET: positron emission tomography
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stratiﬁcation [89]. Exercise and pharmacologic stress
echocardiography are commonly available, less
costly, and well tolerated.
Stress ECHO is suitable for symptomatic disease
with an intermediate pre-test probability of CAD
[90]. The diagnostic goal to detect myocardial
ischemia is deteriorating or emerging wall motion
abnormality. Stress ECHO can be used for the
detection of criteria relevant for the diagnosis and
prognosis of severe CAD (Table 8) [91,92].
3.1.4.5.2.1 Stress echocardiography: limitations and
challenges The diagnostic accuracy of stress ECHO is
signiﬁcantly affected by local expertise, similarly to
routine ECHO. Additionally, study quality is constrained by patient-related variables such as body
build; however, the implementation of contrast
agents may improve image quality and diagnostic
accuracy [93].
3.1.4.5.3. CMR. CMR can be conducted based on
several protocols, such as ﬁrst-pass gadolinium
myocardial enhancement with vasodilator and
dobutamine stress test [94]. Additional insights on
wall motion abnormalities, systolic function, and
areas of ﬁbrosis will be obtained. CMR stress
perfusion imaging was reported to have high
sensitivity and speciﬁcity (90% and 94%, respectively) with a high event-free survival rate for a
negative study (Table 8) [95]. Challenges include a
time-consuming workﬂow and limited expertise for
this test. Moreover, CMR may be contraindicated by
the presence of implanted devices or by severe renal
failure (contraindication of the administration of
gadolinium contrast).
3.1.5. Invasive testing
ICA should not be conducted routinely and is
indicated in case of inconclusive non-invasive

testing in patients with suspected CAD. Early ICA
with no previous non-invasive testing could be
reasonable in several cases, such as high pre-test
probability of CAD, persistent symptoms despite
medical therapy or with typical angina at a low level
of exercise, and a possible high risk of cardiac event
(deﬁned as having survived sudden cardiac death or
potentially life-threatening ventricular arrhythmias
and those patients develop symptoms and signs of
heart failure) based on initial clinical evaluation [1].
Considering the aforementioned limitations of visual stenoses assessment, invasive functional
assessment should integrate fractional ﬂow reserve
(FFR)/Instantaneous wave-free ratio with ICA [96].
That being said, the performance of ICA still carries
a small risk of complications and should remain
dependent on patient preference related to invasive
procedures and revascularization, the expected efﬁcacy of revascularization, as well as choice of
percutaneous coronary intervention (PCI) versus
coronary artery bypass grafting (CABG).
Table 10 offers overall recommendations for initial
diagnostic imaging tests in the assessment of
symptomatic patients with suspected CAD. Diagnostic algorithms for patients with suspected CAD
or known CAD with chest pain are shown in Figs. 3
and 4, respectively.
3.1.6. Patients with suspected ischemia and No
obstructive CAD (INOCA)
Angina with nonobstructive CAD is deﬁned as
“effort-induced angina with positive stress test/MPI
for myocardial ischemia and “normal” or “near
normal” coronary arteries on angiography” [97]. It is
not uncommon in our practice to ﬁnd marked
discrepancy between patient's symptoms, ischemia
on non-invasive testing with non-obstructive

Table 12. Non-pharmacological therapy recommendations.

No

Recommendaon

1

Referral to smoking cessaon clinic is recommended.

2

It is recommended to advise paents to follow the Mediterranean diet and high intake of
fruits and legumes.

3

Sustained physical acvity is recommended.

4

5

It is recommended to advise paents to maintain healthy weight, deﬁned as body mass
index of 18.5 to 24.9 kg/m2, and waist circumference less than 102 cm (40 inches) in men
and less than 88 cm (35 inches) in women
Psychosocial assessment to direct psychological intervenons is recommended.

6

Annual Inﬂuenza vaccinaon may be considered, especially in elderly paents

epicardial vessels [98]. This should suggest the
possibility of non-obstructive cause of ischemia,
most likely as a result of change in intra-microvasculature ﬂow [99]. Coronary microvascular
dysfunction is most like to occur in female patients,
hypertensives, diabetics and patients with other insulin-resistant states [100]. Invasive coronary reactivity testing can be used for the evaluation of
vasospasm as well as nonendothelialedependent
and endothelium-dependent microvascular reactivity (Table 11). Calcium Channel Blockade is
considered a second-line antianginal therapy in
CCS patients but considered the ﬁrst line therapy in
variant angina as the beta blocker
is
contraindicated.
3.2. Non-pharmacological therapy
Controlling risk factors is an essential component
of CCS management in addition to reducing
symptoms and improving prognosis. This can be
achieved through lifestyle modiﬁcation supplemented with appropriate medical therapy for
optimal disease management. Non-pharmacological
interventions carry notable weight in the treatment
of CCS and the improvement of patient survival
[101]. The beneﬁt of lifestyle modiﬁcation in the
prevention of future cardiovascular events is shown
in several studies, notwithstanding the use of secondary prevention therapy and interventions
[102e105]. A multidisciplinary approach should be
targeted to educate and empower patients to

implement appropriate lifestyle and behavior
modiﬁcations, as well as better adhere to their
medication.
As previously mentioned, modiﬁable cardiovascular risk factors are very common in the Saudi
population and include hypertension, dyslipidemia,
obesity, abdominal obesity [2,106e109]. Low
compliance to recommended dietary and physical
activity patterns is frequent [110], and the prevalence of smoking continues to rise [111]. The PURESaudi study revealed the alarming prevalence of
CVD risk factors in the adult Saudi population; of
2047 participants, approximately 70% had low
physical activity, half were obese, 34% followed an
unhealthy diet, 32% had dyslipidemia, 30% were
hypertensive, and 25% were diabetic. Current
smoking, sadness/depression, anxiety and stress
were also relatively prevalent in the Saudi population [32,107]. Gender-based approaches might be
needed in Saudi Arabia seeing as women might
have a higher predisposition to exhibit high risk for
CVD compared to similarly aged men [33,108].
Unfortunately knowledge and awareness of CVD
and CCS risk factors remains relatively limited in
the Saudi population [112,113], highlighting the
need for population-wide as well as individualized
awareness and educational interventions to promote a healthy lifestyle.
Little evidence is available on the efﬁcacy of lifestyle interventions for the modiﬁcation of CVD risk.
A local study investigated the efﬁcacy of a threemonth lifestyle intervention in women aged 30 and

Table 13. Recommendations on the use of anti-anginal agents.

No

Recommendaon

1

Beta-blockers are indicated to control heart rate and symptoms.

2

CCB is the second-line ananginal therapy in paents with contraindicaons to Betablockers, such as variant angina

3

Non-dihydropyridine-CCB is alternave therapy to Beta-blockers for heart rate control if
there is no LV dysfuncon

4

Combinaon of a beta-blocker with a dihydropyridine-CCB should be considered if angina
symptoms are uncontrolled

5

Long-acng nitrates can be considered when inial therapy with a beta-blocker and/or a
CCB is contraindicated, is not well tolerated, or not suﬃcient to control angina symptoms.
Consider a nitrate-free or nitrate-low interval of ~10-14 h to avoid tolerance
Short-acng nitrates are recommended for immediate alleviaon of angina.

6

CCB: Calcium channel blocker;
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above with moderate to high risk of CVD and found
that providing personalized health education, exercise training and diet counselling was associated
with an improvement in the 10-year cardiovascular
Framingham risk score [114]. In a similarly-aged
sample of military personnel in Saudi Arabia, the
National Guard Health Promotion Program for
Chronic Diseases and Comorbid Conditions led to
improvement in modiﬁable risk factors such as body
mass index, waist circumference, blood sugar levels,
and fruits and vegetables consumption [115].
International evidence in support of each lifestyle
intervention will be detailed in the following subsections. Non-pharmacological therapy recommendations are shown in Table 12.

3.2.1. Smoking cessation
Smoking is clearly associated to a greater risk of
cardiovascular diseases, including CCS. An earlier
health survey of 17,350 participants from Saudi
Arabia showed a clear association between smoking and development of CCS [116]. As shown in
the COURAGE trial, greater risk factor control can
improve survival in patients with CCS, with
smoking cessation/no smoking being one of the
strongest predictors of improved 1-year survival
[101]. The decrease in patient mortality was also
reported in other studies in patients with CCS
[117]. Smoking cessation can also help achieve BP
control in younger patients with premature CCS
and thereby decrease the clinical burden of the
disease [118].

Table 14. Recommendations for event prevention.
No

Recommendaon

1

Aspirin 75-100 mg daily is recommended in paents with documented CAD.

2

Clopidogrel 75 mg daily is recommended as an alternave to aspirin in paents with
aspirin intolerance or allergy.

3

Ticagrelor 60mg could be used in combinaon with aspirin in paents post MI.

4

DOAC is recommended in preference to a Vitamin K antagonist in eligible paents with
atrial ﬁbrillaon.

5

The DOAC rivaroxaban 2.5mg twice daily may be considered in paents with CCS and
polyvascular disease

6

Concomitant use of a proton pump inhibitor is recommended in paents receiving aspirin
monotherapy, DAPT, or oral ancoagulant monotherapy with high risk of bleeding.

7

Stans are recommended in all paents with CCS.

8

Combinaon of stan with ezemibe is recommended if treatment goal is not achieved
with stans.

9

Combinaon of stan with a PCSK9 inhibitor (±ezemibe) is recommended in high-risk
populaon who do not achieve LDL-C treatment goals

10

ACE inhibitors (or ARBs) are recommended if a paent has LV systolic dysfuncon,
hypertension, diabetes, or chronic kidney disease.

11

Beta-blockers are recommended in paents with LV dysfuncon, HF and ongoing
symptoms.

12

Hormone replacement therapy is not recommended.

13

Administraon of a proton pump inhibitor is generally not recommended in the absence
of gastrointesnal indicaons

ACE: angiotensin-converng enzyme; ARB: angiotensin receptor blocker; CAD: coronary artery disease;
CCS: chronic coronary syndrome; DAPT: dual anplatelet therapy; DOAC: direct oral ancoagulant; HF:
heart failure; LDL-C: low-density lipid cholesterol; LV: le ventricle; MI: myocardial infarcon; PCSK9:
Proprotein convertase sublisin/kexin type 9;

A Cochrane meta-analysis showed that the use of
one of the forms of nicotine replacement therapy
(gum, transdermal patch, nasal spray, inhalator and
sublingual tablets/lozenges) can lead to up to 60%
higher rates of quitting [119]. The intensity of
additional support provided while using nicotine
replacement therapy can inﬂuence the efﬁcacy of
this approach [119]. Nicotine replacement is an
effective strategy for smoking cessation and should
be considered in combination with behavioral
modiﬁcation. Switching from conventional cigarettes to modiﬁed-risk tobacco products has been
shown to potentially reduce adverse health effects
[120] as well as CVD risk associated with continued
smoking [121]. Individuals who quit conventional
cigarettes and use noncombustible nicotine or tobacco products are at a higher CVD risk compared
to those who abstain from all tobacco products [121].
One study actually suggests that e-cigarettes ensure
a higher rate of sustained 1-year smoking abstinence compared to nicotine replacement therapy
[122]. However, the evidence supporting the superiority of e-cigarettes to placebo or nicotine
replacement therapy remains limited or of low
quality [123e125].
Promoting smoking cessation is therefore important in CCS management and can be achieved
through counselling, behavioral interventions, as
well as pharmacological therapy (including nicotine
replacement).
3.2.2. Healthy diet
Following healthy eating patterns can lead to
clinically meaningful reduction in mortality and
cardiovascular events [126]. The progression of CCS
and other CVDs is inﬂuenced by unhealthy diets
and available evidence supports the ability of
modifying dietary intake of fruits and vegetables to
prevent CVD as well as other non-communicable
diseases such as cancer [127]. In general, a Mediterranean dietary pattern seems to carry a clinically
relevant beneﬁt for the prevention of CVD
[128e130]. Appropriate diets are those that are high
in fruits, vegetables, legumes, ﬁber, monounsaturated fats, nuts, and ﬁsh. In the last decade,
there was a paradigm shift on the concept of diet
and cardiovascular risk related to the balance between carbohydrate and fat, where the earlier is
more harmful than the latter. The PREDIMED trial
showed that fat are not harmful in the usual ranges
consumed by most people and that monounsaturated fatty acid is actually protective while
polyunsaturated fatty acid appear neutral [129].
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3.2.3. Physical activity
Regular physical activity is an independent predictor of improved survival [101] and lower cardiovascular mortality in patients with CCS [131].
Extensive data conﬁrmed that both adopting or
preserving a physically active lifestyle leads to signiﬁcant reductions (up to 50%) of all-cause and
cardiovascular disease mortality in patients with
CCS compared to physical inactivity [132]. Sustained physical activity was also suggested to lead to
more substantial reductions in mortality than
weight loss in coronary heart disease [133]. Vigorous
physical activity up to 2 times weekly shows an association with better cardiac outcomes (all-cause
death, CV death and stroke) in patients with CCS
compared to low-level or no physical activity [134].
High-intensity interval exercise was suggested to be
safe and possibly superior to moderate-intensity
continuous training in patients with CCS, particularly for the improvement of cardiorespiratory
ﬁtness in cardiac rehabilitation [135] and aerobic
capacity [136,137]. Though for more sustainable
physical activities, a 30e40 min a day of brisk
walking for at least four days a week would have
greater impact compared to interrupted physical
activities.
3.2.4. Healthy weight
Overweight and obesity signiﬁcantly increase the
risk of cardiovascular morbidity and mortality, in
addition to the risk of developing CVD at an earlier
age [138]. The implication of obesity might be superior to that of overweight on mortality in patients
with CCS [139]. Regardless, intentional weight loss
was shown to reduce clinical events in patients with
CCS [140]. Weight loss is an effective way to
improve cardiovascular risk proﬁle in CCS patients
with positive implications on body composition, BP
and lipids [141]. Weight loss might be more effective
than exercise in the improvement of atherogenic
lipid proﬁle of CCS patients what are sedentary and
overweight [142].
3.2.5. Psychosocial factors
Patients with CCS, particularly women, were
described to be more vulnerable to psychological
distress, such as anxiety, stress and depression [143].
Psychological stress in CCS patients might have
implications on disease evolution and should
therefore be assessed to improve individualization
of comprehensive rehabilitation programs [144]. A
Cochrane systematic review and meta-analysis
showed that psychological intervention in coronary
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Table 15. Recommendations for revascularization.

heart disease can lead to a signiﬁcant improvement
in psychological symptoms as well as a reduction in
cardiac mortality [145]. Perceived social support
carries a signiﬁcant positive effect on depression
and fatigue in CCS patients [146].
3.2.6. Inﬂuenza vaccination and other viral illnesses
Evidence supports the potential beneﬁt of inﬂuenza vaccination in reducing cardiovascular mortality as well as cardiovascular events in patients
with CVD [147,148] and after a MI [149]. Inﬂuenza
vaccination may therefore be considered for

patients, especially those at higher risk (such as
the elderly). Vaccination against other viral diseases such as COVID-19 may also be beneﬁcial
based on recent evidence, particularly that
many patients infected and admitted with COVID19 have CCS or ischemic equivalents such diabetes
or other CVD [150]. Emerging data suggests that
the risk of one-year incidental cardiovascular
events is higher non vaccinated COVID-19 survivors [151], and that the risk of AMI or stroke can
also be reduced through COVID-19 vaccination
[152].
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Table 15. (Continued).

3.3. Pharmacological therapy
The goal of pharmacological therapy is to control
symptoms, improve quality of life and the prevention of cardiovascular events [153e156].
3.3.1. Anti-anginal therapy
Recommendations for anti-anginal therapy are
shown in Table 13. First choice of treatment is
generally beta-adrenergic blockers. If beta-blockers
are contraindicated or cannot be tolerated, then the
use of calcium channel blockers (CCBs) may be
considered [154,157,158].
Meta-analyses of available evidence suggest second-line or add-on options (to beta-blocker or a
CCB) to include long-acting nitrates, ranolazine,
trimetazidine, and in some cases, ivabradine [158].
When angina relief is needed but initial therapy
with a beta-blocker or non-dihydropyridine CCB is

contraindicated, cannot provide sufﬁcient symptom
control, or is poorly tolerated, clinicians can
consider the use of a long-acting nitrate (e.g. nitroglycerin, isosorbide dinitrate, and isosorbide mononitrate) [159]. Prolonged exposure to nitrates
provokes tolerance with loss of efﬁcacy, which could
be addressed by abstaining from nitrate exposure or
using a low dose of nitrates for an interval of
10e14 h [160]. Short-acting sublingual and spray
nitroglycerin formulations can both provide instant
alleviation of effort angina, with spray nitroglycerin
having a faster onset of action [161]. Furthermore,
the short acting nitrate can be used as a prophylaxis
in patients who are well aware of their pain pattern
and triggers, the short-acting nitrates can be used
prior to the physical (or even psychological) stressor
that will occur, e.g sexual activity or uphill walking.
The beneﬁt of ranolazine monotherapy for CCS
remains uncertain when all evidence is taken
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collectively, but its use as add-on therapy carries
signiﬁcant beneﬁt in the reduction of angina episodes [162]. While ranolazine might reduce the
number of anginal episodes in CCS, it is also linked
to a higher number of adverse effects with no
improvement in mortality of risk of acute MI [163].
That being said, another meta-analysis shows that
the use of ranolazine with a beta blocker or CCB was
beneﬁcial across all examined outcomes [158].
Ranolazine might also lead to signiﬁcant beneﬁt
when added to standard anti-ischemic therapy in
patients after percutaneous coronary revascularization [164]. Regardless, ranolazine is not registered in
SFDA.
Trimetazidine has less consistently reported
beneﬁt in the treatment of CCS [158]. An early metaanalysis of 13 RCTs demonstrated the efﬁcacy of
trimetazidine in patients with CCS compared to
conventional antianginal agents, with a signiﬁcant
improvement on angina attack frequency, weekly
nitroglycerin use and other functional outcomes
[165]. More recent evidence from the retrospective
analysis of an open-label observational study
investigating the safety and efﬁcacy of trimetazidine
(the ATPCI trial) reported similar outcomes,
showing that once daily prolonged-release 80 mg
trimetazidine led to signiﬁcant reductions in the
frequency and severity of angina as well as weekly
short-acting nitroglycerin use independently of
revascularization status [166]. That being said, the
initial analysis of the ATPCI trial failed to show that
the use of twice-daily 35 mg trimetazidine over
several years after successful PCI affects the recurrence of angina or clinical outcomes [167].
Ivabradine reduces the frequency of hospitalization in CCS but does not seem to have a collective
effect on cardiovascular mortality nor the frequency
of CCS episodes [168]. In addition to its unreliable
effect on mortality, the use of ivabradine in patients
with CCS should be limited to HF patients and
those with uncontrolled heart rate despite beta
blockers therapy [169,170].
3.3.2. Event prevention
Recommendations for event prevention are
detailed in Table 14. Supporting evidence is provided in the following sections.
3.3.2.1. Antiplatelet therapy. Low-dose aspirin as single antiplatelet therapy (SAPT) strategy is a pillar of
event prevention in CCS patients while dual antiplatelet therapy (DAPT) with aspirin and an oral
P2Y12 inhibitor and should be used only as a secondary prevention. Evidence suggests that patients

with untimely discontinuation of a P2Y12 inhibitor
are more likely to suffer from stent thrombosis [171].
For optimal beneﬁt and safety, DAPT should be given
for 6 months after PCI [171]. However, a shorter
course of DAPT (3 months) may be considered in
patients who are at a high risk of bleeding but at a very
low risk of stent thrombosis [171].
The THEMIS trial demonstrated that ticagrelor in
combination with aspirin can reduce the risk of
ischemic cardiovascular events in patients with CCS
and diabetes without a history of MI or stroke, albeit
with more occurrence of major bleeding compared
to aspirin alone [172]. The PEGASUS-TIMI 54 trial
also showed a signiﬁcant reduction of the risk of MI,
stroke or cardiovascular death with ticagrelor 60 mg
and 90 mg along with a higher risk of breeding, but
in patients with a previous history of MI [173]. In
general, available evidence support a favorable risk/
beneﬁt ratio with ticagrelor 60 mg in patients with
prior MI [174].
The addition of direct oral anticoagulant (DOAC)
rivaroxaban 2.5 mg to antiplatelet therapy in CCS
was shown to lead to signiﬁcantly less MACE and
ischemic stroke, with a relatively low risk of major
bleeding [175,176].
3.3.2.2. Lipid-lowering therapy. The management of
dyslipidemia is necessary in patients with CCS who
are at high risk of cardiovascular events and should
include both a lifestyle and pharmacological
component consistently with available lipid guidelines. In regards to medical therapy, statins must be
considered to lower LDL-C levels and have been
shown to be effective especially in high-dose regimens, alone or in combination with ezetimibe [177].
The reduction of LDL-C levels with intensive therapy after acute coronary events carries a signiﬁcant
positive effect on long-term cardiovascular outcomes [178]. Intensive statin therapy was suggested
to confer a higher degree of reduction in the risk of
stroke in patients with CCS compared to standard
statin therapy [179]. The addition of other drugs
such as ezetimibe is justiﬁed in case target lipid
levels could not be achieved with statins alone. To
note that a meta-analysis showed that ezetimibe can
ensure more reduction in LDL-C in patients with
high CVD already on statins compared to doubling
the dose of statin therapy [180]. PCSK9 monoclonal
antibodies can also be beneﬁcial in patients who
cannot receive other lipid lowering drugs or could
not achieve target LDL levels [181], albeit at a high
cost often limiting their accessibility.
Pre-treatment with high-dose statin has been
consistently shown to be beneﬁcial in reducing the

risk of complications and major adverse cardiac
events after percutaneous coronary intervention
(PCI) [182,183].
Current Saudi Guidelines for Dyslipidemia Management recommend a treatment goal for LDL
cholesterol of <1.4 mmol/L (<55 mg/dL) for veryhigh-risk patients and of <1 mmol/L in extremely
high-risk group with recurrent cardiac events [184].
3.3.2.3. Renin-angiotensin-Aldosterone blocker therapy. In patients with CCS without HF, renin
angiotensin system inhibitors (RASi) were found to
be beneﬁcial in reducing cardiovascular events and
mortality only when compared to placebo, with this
beneﬁt lost when RASi are compared to active
controls [185]. While the use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin
receptor blockers (ARBs) might be questioned in
CCS patients without HF [186], RASi have also been
reported to reduce the occurrence of HF and cardiovascular events in individuals with high CVD
risk and atrial ﬁbrillation [187]. The use of RASi
might be better limited to CCS patients with other
indications for this therapy, such as concomitant
hypertension, LV dysfunction, diabetes or chronic
kidney disease.
3.3.2.4. Other therapies
3.3.2.4.1. Proton pump inhibitors. Proton pump inhibitors that inhibit CYP2C19, particularly omeprazole and esomeprazole, have been suggested to
dampen the pharmacodynamic response to clopidogrel. It is therefore not recommended to administer omeprazole or esomeprazole with clopidogrel
in the absence of gastrointestinal indications [188].
3.3.2.4.2. Hormone replacement therapy. Available
RCTs have failed to show a prognostic beneﬁt with
hormone replacement therapy provides, which was
shown to lead to an increased CVD risk in women
aged >60 years [189]. Hormone replacement therapy
should not be used.
3.4. Revascularization
Contemporary international chronic coronary
syndrome guidelines consider myocardial revascularization as a second line therapy to optimal medical therapy to improve symptoms in case the
patient remained symptomatic. However, a single
center study in Qassim Saudi Arabia showed
optimal medical therapy is achieved in only 10% of
the study cohort. Therefore, it is important to
improve clinical management of CCS and
adequately fulﬁl ﬁrst line therapy before considering myocardial revascularization in local
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populations [190]. Although there is a mortality
beneﬁt of revascularization in selected cases, such as
left main disease, severe LV dysfunction, proximal
left anterior descending (LAD) artery disease and
diabetics [191], available evidence shows no
improvement of survival in the general CCS population with myocardial revascularization; in the
ISCHEMIA trial, initial myocardial revascularization by Percutaneous Coronary Intervention (PCI)
or Coronary Artery Bypass Graft (CABG) surgery
showed no mortality beneﬁt compared to initial
optimal medical therapy in patients with CCS and
moderate or severe ischemia [46]. Several current
meta-analyses demonstrate that the survival
advantage observed in chronic coronary syndrome
patients with medical therapy cannot be improved
with the addition of revascularization [192e194].
When exploring the implication of the number of
diseased vessels and the degree of ischemia based
on data from the COURAGE trial, the association
between the number of diseased vessels (but not
ischemia) and mortality after PCI was evident in
univariate analysis but did not persist after accounting for baseline variables [195]. Very limited
evidence is available from Saudi Arabia. One study
showed that long-term risk of cardiac-related deaths
after surgical revascularization (CABG) in CCS is
not inﬂuenced by pre-operative signiﬁcant
myocardial ischemia and ventricular dysfunction
[196].
Conversely, while the degree of ischemia was not
associated with any changes in risk, some beneﬁt
(6.3% decrease) was observed with invasive therapy
in the patient group with the highest CAD severity
on the level of cardiovascular death or MI in the
long-term outcomes of the ISCHEMIA trial [197]. It
is very important to recognize that not all available
data are in concordance, and several patient categories (namely those with multivessel disease with
impaired LV function, advanced kidney disease,
prior revascularization, left main disease, advanced
age and complex heart disease) were excluded from
the trials based on which the conclusions about the
lack of survival advantage with revascularization
were made. A deep dive into available data reveals
clear exceptions to the lack of survival beneﬁt with
myocardial revascularization. In direct opposition to
the ISCHEMIA trial and other studies, the degree of
ischemia was suggested in a meta-analysis to affect
the beneﬁt that can be expected from myocardial
revascularization; while patients with no ischemia
might not expect myocardial revascularization to
reduce the incidence of MACE or death compared
to medical therapy, those with objective evidence of
moderate to severe ischemia will beneﬁt in terms of
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MACE incidence reduction [198]. More importantly,
survival beneﬁts can be expected in addition to a
lower incidence of MACE with revascularization in
patients who have severe ischemia [198]. Evidence
therefore suggest to a survival advantage in patients
undergoing early revascularization with greater
extent of ischemia, as evidenced on PET MPI [199].
A sub-analysis of the EXCEL (XIENCE versus
Coronary Artery Bypass Surgery for Effectiveness of
Left Main Revascularization) trial showed that
CABG and PCI with everolimus-eluting stents are
comparable in terms of a composite measure of
death, MI, or stroke among patients with left main
CAD, irrespective of baseline anatomic complexity
and the extent of CAD [200]. However, PCI was
associated with signiﬁcantly more frequent major
adverse cardiac event or ischemia-driven revascularization compared to CABG, especially with
increasing SYNTHAX scores [200]. In the G-LM
(Gulf Left Main) registry for unprotected left main
coronary artery disease in 2138 underwent PCI or
CABG, showed comparable outcomes between
those treated with PCI and CABG (rates of freedom
from revascularization, MACCE, or total mortality)
after a follow-up of 15 months. Similarly, comparable survival was observed after PCI and CABG in
patients with single-vessel, proximal LAD disease,
but CABG provided more effective angina relief and
less need for repeat revascularizations [201]. In the
SYNTHAX trial, it was also evident that CABG is
preferable to PCI for revascularization as it leads to
less death (all causes), stroke, MI, or repeat revascularization in patients with 3 vessel disease or left
main disease [202], especially those with concomitant diabetes [203]. In the same vein, the FREEDOM
trial showed PCI to be inferior to CABG in patients
with advanced CAD (multivessel) and diabetes;
CABG led to a less all-cause mortality and non-fatal
MI compared to PCI, albeit with higher rates of
stroke [204]. The superiority of CABG in diabetic
patients was also reported in a pooled analysis from
major trials (e.g. COURAGE [Clinical Outcomes
Utilizing Revascularization and Aggressive Drug
Evaluation], BARI 2D [Bypass Angioplasty Revascularization Investigation 2 Diabetes], and
FREEDOM [Future Revascularization Evaluation in
Patients with Diabetes Mellitus: Optimal Management of Multi-vessel Disease]) [205]. This study also
noted a non-signiﬁcant but positive trend towards
improved rates of all-cause death, MI, or stroke with
CABG in patients with concomitant diabetes and
chronic kidney disease [205].

In conclusion, conservative medical therapy is
preferable for the ﬁrst-line treatment of CCS in the
absence of a compelling indication. Revascularization should be considered in certain clinical scenarios, as detailed in Table 15. The choice of
revascularization should be personalized and subject to patient preference as well as multi-disciplinary heart team discussions regardless of the
presence or absence of a compelling indication.
Clinical characteristics, disease complexity and
technical feasibility should also inform the choice of
revascularization.
3.5. Impact of the COVID-19 pandemic
The coronavirus disease 2019 (COVID-19)
pandemic and the ensuing lockdowns impacted not
only patient's adherence to lifestyle and therapies
but also access to care. In a French study involving
195 patients with mean age of 65.5 years, 3% of
patients discontinued their medications while 85%
remained adherent to the recommended daily
intake of prescribed aspirin. However, adherence to
recommended lifestyle was lower, with close to half
of patients reporting more than 25% reduction in
physical activity, and around a quarter of patients
reporting body weight gain of more than 2 Kgs. This
was reported in addition to an increase in tobacco
consumption among smokers [206]. Moreover, the
mortality of patients with COVID-19 is higher
among those with comorbidities such as CVD, hypertension, diabetes, congestive HF, chronic kidney
disease and cancer compared to those without [207].
Worse clinical outcomes and death after COVID-19
were also reported and could be predicted among
patients with pre-existing inﬂammatory conditions
(related to conditions such as chronic coronary diseases, type 2 diabetes mellitus or obesity). A notable
example is the possibility of COVID-19 disease and
its inherent cytokine storm triggering or predisposing patients for the rupture of a silent atheromatous plaque. This would lead to sudden clinical
deterioration as a result of the arising ACS [208]. It is
clear that by impeding the delivery of patient care,
the COVID-19 pandemic led to a notable decrease
in patient safety and treatment efﬁcacy. To note that
cardiac CT was utilized more frequently in North
America during the COVID-19 pandemic due to
some advantages in certain cases, namely: (1) the
need to distinguish between myocardial injury and
MI; (2) presentation with acute chest pain; (3) cases
of disease with concomitant stable chest pain; (4)

suspected intracardiac thrombus; (5) concomitant
valvular heart disease [209]. Moreover, PCI rates
decreased during the pandemic as signiﬁcantly
fewer patients underwent elective PCI in England as
reported by the British Cardiovascular Intervention
Society [210].
3.6. Cardiac rehabilitation
Exercise-based cardiac rehabilitation was shown
to be beneﬁcial to patients with chronic heart disease. This approach leads to lower rates of MI,
possibly fewer deaths from all causes, substantially
less all-cause hospitalization and associated
healthcare costs, as well as better quality of life for
up to 12 months. Long-term beneﬁts have been
suggested to include a protective effect against cardiovascular mortality and MI [211]. One study
showed that a phase 2 cardiac rehabilitation program in patients with CCS can lead to an
improvement in CVD risk factors in both obese and
non-obese patients. To note that obese patients
show a greater decrease in BMI, BP, and LDL-C
levels [212]. Participation of patients with CCS in an
exercise-based cardiac rehabilitation program was
also associated with signiﬁcantly less frequent
angina and improved exercise capacity [213]. A
retrospective cohort study that was conducted online on real-world dataset of CCS patients showed a
lower risk of all-cause mortality, rehospitalization
and cardiovascular morbidity 1.5 years after diagnosis among patients who underwent exercisebased cardiac rehabilitation compared to those who
were referred to PCI. Moreover, the beneﬁt of exercise-based cardiac rehabilitation persisted in
several regards (all-cause mortality, rehospitalization, acute MI or stroke) with or without the addition of PCI [214]. A home-based cardiac
rehabilitation program with remote monitoring for
frail patients with the help of home physiotherapist
and a care giver is feasible for patients with logistical problems attending center -based cardiac
rehabilitation programs. The program should cover
exercise training, risk factors management (dietary
education, smoking cessation) medication management and psychological support. The safety and
efﬁcacy of this requires further evaluation [215,216].
Reducing and preventing cardiovascular events
through a phase 3 cardiac rehabilitation carries an
established beneﬁt even in elderly patients with
CCS [217]. Finally, outcomes of cardiac rehabilitation in low to moderate risk CAD patients are
comparable between programs delivered via telehealth and center-based supervised program. This
offers the opportunity to address cardiac
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rehabilitation access issues that might be faced by
some patients through the use of telehealth intervention as an alternative for center-based cardiac
rehabilitation [218].

4. Conclusions
Over two million patients suffer from CCS in
Saudi Arabia. Only a minority of patients achieve
optimal medical therapy. These guidelines which
are evidence based when implemented will improve
the care of patients with CCS and will lead to more
appropriate use of available resources. It can be not
be overemphasized that a cornerstone of successful
management is control of CCS risk factors.
Adequate control of risk factors with optimal
achievements of targets for weight, HbA1c, LDL, BP
as well as smoking cessation in addition to being
involved in either a formal cardiac rehabilitation
program or being engaged in regular physical exercise is likely to prevent the onset of acute coronary
events in patients with CCS. When symptoms
persist the appropriate and timely use of revascularization either by PCI or CABG is likely to relieve
symptoms and improve outcomes.
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